Elevate Your CLL Research with Briya’s Dynamic Datasets

Unlock deeper understanding of Chronic Lymphocytic Leukemia with Briya’s comprehensive and adaptive dataset.

CLL Image
CLL Image

Request Your Dataset Now

The Briya CLL Dynamic Dataset Coverage includes:

  • Over 3000 patient records from multiple sites
  • Clinical Assessments: Lymphocyte Count, Rai Staging (stages 0 to IV), Binet Staging (A, B, C), Physical Examination (lymphadenopathy, splenomegaly, or hepatomegaly)
  • Immunophenotyping: Flow Cytometry (CD5, CD19, CD20, CD45, CD200, CD23, CD38, and ZAP-70), IGHV Mutation Status (NOTCH1, SF3B1, BIRC3, ATM mutations)
  • Genetic and Molecular Testing: FISH (deletions at 13q14, 11q22-23, and 17p13), TP53 Mutation
  • Laboratory Tests: Complete Blood Count, Beta-2 Microglobulin Levels, LDH, Serum Free Light Chains
  • Imaging Data: CT Scans, Ultrasound, MRI
  • Procedures: Bone Marrow Biopsy, Hematopoietic Stem Cell Transplantation (HSCT), Splenectomy, Radiation Therapy
  • Treatments: Immunotherapy, Chemotherapy and biological agents
CLL Image

Better Understanding of CLL with Briya’s Real-World Datasets

Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults, accounting for about one in three new cases of leukemia in the U.S. The condition exhibits a high degree of genetic variability and interpatient heterogeneity, leading to a clinical course that can range from indolent to aggressive progression.

With a patient’s genetic alterations significantly impacting the disease’s prognosis and evolution, insights into mutations play a major role in understanding disease heterogeneity and treatment outcomes. There is a need for additional data on the response to approved targeted therapies in patients carrying recurrent mutations beyond TP53.

For researchers developing novel therapies, the need for deeper insights into CLL’s biological complexities—including genetic, molecular, and clinical factors—is evident.

Briya’s Dynamic Datasets offer unparalleled and comprehensive insights into unique genomic profile, disease progression and prognosis. Researchers can access thousands of anonymized patient records, including detailed demographics, treatment histories, and clinical data and outcomes. By aggregating and curating high-quality, diverse data, Briya provides valuable tools to accelerate discovery and bring innovative treatments to market faster.

Our dataset supports hypothesis generation, biomarker discovery, and clinical trial design.

CLL Image

Benefits of the Dynamic Dataset

Extensive
Data Coverage

Access a high number of cases, even for ultra-rare conditions, enabling more robust and reliable research outcomes.

Comprehensive
Patient Journey

Track detailed patient journeys from diagnosis to treatment outcomes, offering a holistic view of rare disease progression and management.

High-Quality,
De-identified Data

All data is de-identified and standardized, ensuring compliance with privacy regulations while retaining the richness of clinical details.

Group-67184.svg

Seamless
Integration

Our datasets are ready for integration into your research or analytics platforms, making data access straightforward and efficient.

Explore Your
Dynamic Dataset